1. ACE Inhibition in Hypertension

   • John R. Cockcroft

   Review Article 17 August 2012 Pages: 303 - 317

   

2. Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus

   • Odd Erik Johansen
   • Kåre I. Birkeland

   Review Article 17 August 2012 Pages: 319 - 335

   

3. The Tragedy of TRIUMPH for Nitric Oxide Synthesis Inhibition in Cardiogenic Shock

   • Alison Bailey
   • Theodore W. Pope
   • Charles L. Campbell

   Review Article 17 August 2012 Pages: 337 - 345

   

4. Dose-Response Characteristics of Olmesartan Medoxomil and Other Angiotensin Receptor Antagonists

   • David H. G. Smith

   Review Article 17 August 2012 Pages: 347 - 356

   

5. Flaws in Dose-Finding of Antihypertensive Drugs

   • George S. Stergiou

   Commentary 17 August 2012 Pages: 357 - 359

6. Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate

   • Dean J. Kereiakes
   • Joel M. Neutel
   • Robert Dubiel

   Original Research Article 17 August 2012 Pages: 361 - 372

   

7. Effects of ACE Inhibitors or ↓-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial

   • Jalal K. Ghali
   • S. William Tam
   • A-HeFT Investigators

   Original Research Article 17 August 2012 Pages: 373 - 380

   

8. Treatment and Control of BP and Lipids in Patients with Hypertension and Additional Risk Factors

   • Verna Welch
   • Simon S. K. Tang

   Original Research Article 17 August 2012 Pages: 381 - 389